Phase III data show significant overall survival benefit of afatinib compared to erlotinib in patients with SCC
6 July 2015 | By Victoria White
Results from the LUX-Lung 8 Trial demonstrate that afatinib resulted in superior progression-free survival and overall survival compared to erlotinib...